A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring
Brett Fleisher, Sihem Ait-Oudhia Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA Background: Biologics have gained traction for use in oncology, but have demonstrate clinical variability for efficacy and...
Main Authors: | Fleisher B, Ait-Oudhia S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-12-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/a-retrospective-examination-of-the-us-food-and-drug-administrations-cl-peer-reviewed-article-OTT |
Similar Items
-
A framework for economic evaluation of therapeutic drug monitoring—guided dosing in oncology
by: Daniel Erku, et al.
Published: (2021-10-01) -
An Educational Program for Nurses on Therapeutic Misconception in the Oncology Setting
by: Magnanelli, Debra
Published: (2015) -
Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology
by: Amelia-Naomi Sabo, et al.
Published: (2021-03-01) -
Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
by: Sandrine Niyongere, et al.
Published: (2020-06-01) -
Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial
by: SN Bondarenko, et al.
Published: (2019-03-01)